secwatch / observer
8-K filed December 30, 2025, 6:59 PM ET ticker OTLC CIK 0000908259
debt confidence high sentiment neutral materiality 0.60

Oncotelic closes initial $800K convertible note offering at 12% with warrants

Oncotelic Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Oncotelic Therapeutics, Inc. issued each Note convertible into up to 250,000 shares of Oncotelic's Common Stock of convertible note to 21 accredited investors for conversion price $0.10 per share.

Security
convertible note
Shares
each Note convertible into up to 250,000 shares of Oncotelic's Common Stock
Purchaser
21 accredited investors
Consideration
conversion price $0.10 per share
Exact text from the filing
Each Note will be convertible into up to 250,000 shares of Oncotelic's Common Stock (conversion price $0.10 per share)
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Oncotelic Therapeutics, Inc. issued 250,000 Warrants per Unit of warrant to 21 accredited investors.

Security
warrant
Shares
250,000 Warrants per Unit
Purchaser
21 accredited investors
Exact text from the filing
Each Unit will also consist of 250,000 (the "Warrants") each to purchase one share of Oncotelic's Common Stock at $0.12 per share
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Oncotelic Therapeutics, Inc. issued 32 units of unit to 21 accredited investors for $25,000.00 per Unit.

Security
unit
Shares
32 units
Purchaser
21 accredited investors
Consideration
$25,000.00 per Unit
Exact text from the filing
) unit s (th e “Units” ) bein g conducte d b y Maker . Each Unit consists of one note issued by the Company (a “Note” and collectively, the “Notes”), in the principal amount of $25,000.00, bearing annual interest at the rate of 12% and due and payable on the 2-year anniversary of the final closing of the Offering. Each Note will be convertible into up to 250,000
View on SEC.gov

Browse all equity issuances →

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-25-029634
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.